
    
      This Phase II study will be a randomized, double blind, placebo controlled study of BSYX-A110
      in very low birth weight neonates. A total of 80 infants will be dosed in this study.
      Participants will receive either BSYX-A110 or placebo, at 60 mg/kg or 90 mg/kg. The Study
      Drug will be administered at 48-120 hours of life, 7 days after the initial dose, and 14 days
      after the initial dose for all dose groups.
    
  